Teleflex Incorporated TFX posted fourth-quarter 2024 adjusted earnings per share (EPS) from continuing operations of $3.89, ...

Teleflex to create a new, independent publicly traded company consisting of its Urology, Acute Care, and OEM businesses.

Piper Sandler analyst Matt O’Brien downgraded Teleflex (TFX) to Neutral from Overweight with a price target of $140, down from $255. The ...

After the split, Teleflex would focus on devices for bloodstream and heart procedures, along with medical imaging, while ...

Teleflex Incorporated announced a plan to separate the company’s urology, acute care, and original equipment manufacture ...

Teleflex experienced a dramatic 20% stock plunge on Thursday, hitting a new 52-week low of $136.60. Despite slightly exceeding analyst expectations with an adjusted earnings per share of $3.89, the ...

Teleflex Incorporated (NYSE: TFX) (the "Company") today announced financial results for the fourth quarter ended December 31, 2024. Fourth quarter financial ...

NEW YORK - Teleflex Incorporated (NYSE: TFX) saw its shares tumble over 21% on Tuesday after the medical technology company reported fourth quarter results that missed revenue exp ...

Teleflex shares tumbled to a 52-week low on Thursday after the medical-technology company posted disappointing financial guidance and unveiled plans for a nearly $800 million acquisition and a spinoff ...

Teleflex to separate into two companies by mid-2026 and acquire Biotronik's Vascular Intervention unit for €760 million. CFO ...

Teleflex has announced a plan to split its business into two separate independent companies—and it’s setting up one of its ...

Biotronik today announced a strategic shift that includes the divestiture of its Vascular Intervention (VI) business to ...